Business club on December 25 - ask if companies want to delve into the cultural and apply to the enterprise actual operation and management? The answer is: "to!" Cost pressures in the raw materials, pharmaceutical prices surge, the new GMP certification related regulations of the state, forcing pharmaceutical companies increase technical reformation investment and operating costs, such as medicine, under the influence of the economic environment changes enterprise want to play the more surprising "culture card"? Answer is for sure: "should, of course!" Pharmaceutical companies want to in the intensified market competition foothold, and successful transformation, the "culture" into the enterprise marketing management of can yet be regarded as a welcome antidote.
Lao tze said on the daodejing: "ZhiRenZhe wisdom, knew who." Culture in the management of drug firms have to be reckoned with in the role. If drug companies continue to wandering in the don't even know it's culture, will gradually abandoned by the market, the enterprise operation into chaos, and eventually die. Drug companies new product research and development, product upgrade and maintenance, the execution and evaluation of the new system, the management of the marketing team ability, executive ability and the sense of responsibility, so that the marketing performance of ascension and create greater value and so on all need to some extent drug firms to forge by means of the culture.
Culture can improve enterprise's marketing performance, change the management structure. Improve marketing management should be an important index of attention of many drug companies that doesn't require excessive refinement, but in basic part and the key points to control the strength, in addition to comb the organization and the flow of marketing, set up a practical system, and find the key point of customer satisfaction, will be the most basic of "culture" into business operation level make cognitive becomes clear, and gradually find their own direction, is a prerequisite for drug firms change development. |
